Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparathyroidism

NEXT STORY
Outlook on the Surgical Site Infection Control Global Market to 2028 – Impact Analysis of COVID-19
PREV STORY
Kura Oncology to Present at J.P. Morgan Healthcare Conference
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate

Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate Tokyo, ...

author_avatar
NASDAQ Market News

Eastern Equine Encephalitis – Pipeline Review, H1 2020

author_avatar
NASDAQ Market News

Strados Labs Adds Health Leaders to Management Team

Seasoned Executives Bring Deep Experience to Remote Cardiopulmonary Monitoring Start-UpPHILADELPHIA, Feb. 12, 2019 (GLOBE ...

author_avatar
NASDAQ Market News